Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009

Journal of Child and Adolescent Psychopharmacology

Volumn 24, Issue 5, 2014, Pages 260-268

  Betts, Keith A ^a   Sikirica, Vanja ^b   Hodgkins, Paul ^b   Zhou, Zhou ^a   Xie, Jipan ^a   Deleon, Anthony ^b   Erder, M Haim ^b   Wu, Eric Q ^a  

^a ANALYSIS GROUP   (United States)

^b SHIRE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CLONIDINE; GUANFACINE; METHYLPHENIDATE; NEUROLEPTIC AGENT; PSYCHOTROPIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; COMORBIDITY; DRUG INDICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PSYCHOPHARMACOTHERAPY; UNITED STATES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; COMPLICATION; DRUG COMBINATION; FACTUAL DATABASE; MENTAL DISORDERS;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MENTAL DISORDERS; PREVALENCE; PSYCHOTROPIC DRUGS; UNITED STATES;

EID: 84903131632     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2013.0107     Document Type: Article

References (51)

1. Akinbami LJ, Liu X, Pastor PNP, Reuben CCA, Akinbami O: Attention deficit hyperactivity disorder among children aged 5-17 years in the United States, 1998-2009. NCHS Data Brief 1-8, 2011
2. Alexander GC, Gallagher SA, Mascola A, Moloney RM, Stafford RS: Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiol Drug Saf 20:177-184, 2011
3. Banaschewski T, Roessner V, Dittmann RW, Santosh PJ, Rothenberger A: Non-stimulant medications in the treatment of ADHD. Eur Child Adolesc Psychiatry 13 Suppl 1:I102-116, 2004
4. Bhatara V, Feil M, Hoagwood K, Vitiello B, Zima B: National trends in concomitant psychotropic medication with stimulants in pediatric visits: Practice versus knowledge. J Atten Disord 7:217-226, 2004
5. Biederman J, Mick E, Faraone S V, Braaten E, Doyle A, Spencer T, Wilens TE, Frazier E, Johnson MA: Influence of gender on attention deficit hyperactivity disorder in children referred to a psychiatric clinic. Am J Psychiatry 159:36-42, 2002
6. Bussing R, Winterstein AG: Polypharmacy in attention deficit hyperactivity disorder treatment: Current status, challenges and next steps. Curr Psychiatry Rep 14:447-449, 2012
7. Bussing R, Zima BT, Belin TR: Variations in ADHD treatment among special education students. J Am Acad Child Adolesc Psychiatry 37:968-976, 1998
8. Chen C-Y, Gerhard T, Winterstein AG: Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 19:187-195, 2009
9. Childress AC: Guanfacine extended release as adjunctive therapy to psychostimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Adv Ther 29:385-400, 2012
10. Chronis AM, Pelham WE, Gnagy EM, Roberts JE, Aronoff HR: The impact of late-Afternoon stimulant dosing for children with ADHD on parent and parent-child domains. J Clin Child Adolesc Psychol 32:118-126, 2003
11. Comer JS, Olfson M, Mojtabai R: National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 49:1001-1010, 2010
12. Constantine R, Tandon R: Changing trends in pediatric antipsychotic use in Florida's Medicaid program. Psychiatr Serv 59:1162-1168, 2008
13. Cooper WO, Arbogast PG, Ding H, Hickson GB, Fuchs DC, Ray WA: Trends in prescribing of antipsychotic medications for US children. Ambul Pediatr 6:79-83, 2006
14. Cooper WO, Hickson GB, Fuchs C, Arbogast PG, Ray WA: New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 158:753-759, 2004
15. Crystal S, Olfson M, Huang C, Pincus H, Gerhard T: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood) 28:770-781, 2009
16. Czaja AS, Valuck R: Off-label antidepressant use in children and adolescents compared with young adults: Extent and level of evidence. Pharmacoepidemiol Drug Saf 21:997-1004, 2012
17. Doshi JA, Hodgkins P, Kahle J, Sikirica V, Cangelosi MJ, Setyawan J, Erder MH, Neumann PJ: Economic impact of childhood and adult attention-deficit/hyperactivity disorder in the United States. J Am Acad Child Adolesc Psychiatry 51:990-1002.e2, 2012
18. Dosreis S, Zito JM, Safer DJ, Gardner JF, Puccia KB, Owens PL: Multiple psychotropic medication use for youths: A two-state comparison. J Child Adolesc Psychopharmacol 15:68-77, 2005
19. Duffy FF, Narrow WE, Rae DS, West JC, Zarin DA, Rubio-Stipec M, Pincus HA, Regier DA: Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 15:12-25, 2005
20. Elbe D: May we have your attention please: An update on attention deficit/hyperactivity disorder pharmacotherapy. Pharm. Pract. Natl. Contin. Educ. Program, July/August 2011
21. Epstein MA, Shaywitz SE, Shaywitz BA, Woolston JL: The boundaries of attention deficit disorder. J Learn Disabil 24:78-86, 1991
22. Findling RL, Steiner H, Weller EB: Use of antipsychotics in children and adolescents. J Clin Psychiatry 66 Suppl 7:29-40, 2005
23. Fulton BD, Scheffler RM, Hinshaw SP, Levine P, Stone S, Brown TT, Modrek S: National variation of ADHD diagnostic prevalence and medication use: Health care providers and education policies. Psychiatr Serv 60:1075-1083, 2009
24. Jensen PS, Garcia JA, Glied S, Crowe M, Foster M, Schlander M, Hinshaw S, Vitiello B, Arnold LE, Elliott G, Hechtman L, Newcorn JH, Pelham WE, Swanson J, Wells K: Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD. Am J Psychiatry 162:1628-1636, 2005
25. Kaiser Commission on Medicaid and the Uninsured: Medicaid: A Primer. Washington, DC: The Henry J. Kaiser Family Foundation, 2013. Available at: Http://kaiserfamilyfoundation.files.wordpress.com/2010/06/7334-05.pdf. Last accessed 23 April 2014
26. Larson K, Russ SA, Kahn RS, Halfon N: Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 127:462-470, 2011
27. Maglione M, Maher AR, Hu J, Wang Z, Shanman R, Shekelle PG, Roth B, Hilton L, Suttorp MJ, Ewing BA: Off-Label Use of Atypical Antipsychotics: An Update. Comp Eff Rev No. 43. Rockville, MD: Agency for Healthcare Research and Quality (US); 2011
28. Martin A, Van Hoof T, Stubbe D, Sherwin T, Scahill L: Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care. Psychiatr Serv 54:72-77, 2003
29. Matone M, Localio R, Huang Y-S, DosReis S, Feudtner C, Rubin D: The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: A national study of U.S. Medicaid-enrolled children. Health Serv Res 47:1836-1860, 2012
30. May DE, Kratochvil CJ: Attention-deficit hyperactivity disorder: Recent advances in paediatric pharmacotherapy. Drugs 70:15-40, 2010
31. Ming X, Mulvey M, Mohanty S, Patel V: Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. Adolesc Health Med Ther 2:105-112, 2011
32. Pappadopulos E, Jensen PS, Schur SB, MacIntyre JC, Ketner S, Van Orden K, Sverd J, Sardana S, Woodlock D, Schweitzer R, Rube D: ''Real world'' atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull 28:111-121, 2002
33. Pastor PN, Reuben CA, Centers for Disease Control and Prevention: Diagnosed attention deficit hyperactivity disorder and learning disability: United States, 2004-2006. Vital Health Stat 10:1-14, 2008
34. Pathak P, West D, Martin BC, Helm ME, Henderson C: Evidencebased use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005. Psychiatr Serv 61:123-129, 2010a.
35. Pathak P, West D, Martin BC: Weighing the evidence for pediatric antipsychotic use. Psychiatr Serv 61:325, 2010b.
36. Penzner JB, Dudas M, Saito E, Olshanskiy V, Parikh UH, Kapoor S, Chekuri R, Gadaleta D, Avedon J, Sheridan EM, Randell J, Malhotra AK, Kane JM, Correll CU: Lack of effect of stimulant combination with second-generation antipsychotics on weight gain, metabolic changes, prolactin levels, and sedation in youth with clinically relevant aggression or oppositionality. J Child Adolesc Psychopharmacol 19:563-573, 2009
37. Pliszka SR: Non-stimulant treatment of attention-deficit/hyperactivity disorder. CNS Spectr 8:253-8, 2003
38. Pohl G, Van Brunt D: A retrospective claims analysis of combination therapy in the treatment of adult attention-deficit/hyperactivity disorder (ADHD). BMC Health Serv Res 9:95, 2009
39. Safer DJ: Concomitant psychotropic medication for youths. Am J Psychiatry 160:438-449, 2003
40. Sikirica V, Erder MH, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ: Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents. Pharmacoeconomics 30:e1-15, 2012a.
41. Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ: Comparative treatment patterns, resource utilization, and costs in stimulanttreated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-Antipsychotics. J Manag Care Pharm 18:676-689, 2012b.
42. Sikirica V, Xie J, He T, Erder MH, Hodgkins P, Yang H, Samuelson T, Wu EQ: Guanfacine immediate-versus extended release for treatment of attention deficit/hyperactivity disorder (ADHD). Am J Pharm Benefits 5:e84-e94, 2013
43. Spencer T, Biederman J: Non-stimulant treatment for attention-deficit/ hyperactivity disorder. J Atten Disord 6 Suppl 1:S109-119, 2002
44. Strange BC: Once-daily treatment of ADHD with guanfacine: Patient implications. Neuropsychiatr Dis Treat 4:499-506, 2008
45. Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A: Attention-deficit/hyperactivity disorder: Increased costs for patients and their families. J Am Acad Child Adolesc Psychiatry 42:1415-1423, 2003
46. Weiss M, Panagiotopoulos C, Giles L, Gibbins C, Ph D, Kuzeljevic B, Davidson J, Harrison R: A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol 19:575-582, 2009
47. Wilens TE: Combined pharmacotherapy in pediatric psychopharmacology: Friend or foe? J Child Adolesc Psychopharmacol 19:483-484, 2009
48. Wolraich M, Brown L, Brown RT, DuPaul G, Earls M, Feldman HM, Ganiats TG, Kaplanek B, Meyer B, Perrin J, Pierce K, Reiff M, Stein MT, Visser S: ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 128:1007-1022, 2011
49. Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH: Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: A systematic literature review. CNS Drugs 26:581-600, 2012
50. Yanofski J: The dopamine dilemma: Using stimulants and antipsychotics concurrently. Psychiatry (Edgmont) 7:18-23, 2010
51. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL: Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2:24, 2008